Effect of cimicifuga racemosa on menopausal syndrome caused by LHRH-a in breast cancer.

What Was Tested

The paper reports a study of Gonadorelin, published as a randomized controlled trial.

This perspective randomised-design study is to investigate the effect and safety of cimicifuga racemosa on MPS induced by LHRH-a in breast cancer (clinical trial registered: NCT03339882).

Why It Was Studied

However, its clinical value in treating with MPS induced by luteinizing-hormone releasing hormone analogue (LHRH-a) therapy of pre-/peri-menopausal breast cancer patients is still unknown.

Who Took Part

PubMed indexes the participants as adults, women only.

Breast cancer patients planning for LHRH-a treatment were randomly divided into 2 groups.

The control group which was being treated with the standard treatment of LHRH-a.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Gonadorelin group and the comparison group should start out alike.

The other group was being treated with Remifemin, the commercialized product of cimicifuga racemose extract, combined with LHRH-a, called Remifemin group.

Their main endpoint was Kupperman menopause index (KMI).

Hormone levels in peripheral blood and gynecological complications were also evaluated.

What Was Measured

The subject headings attached to it are Breast Neoplasms, Cimicifuga, Gonadotropin-Releasing Hormone, Menopause, Premature, Phytotherapy, Plant Extracts and Syndrome.

Author keywords: Breast cancer, Cimicifuga racemosa, Luteinizing-hormone releasing hormone analogue and Menopause syndrome.

What This Means in Plain Language

The paper is a randomized study of Gonadorelin.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Journal of ethnopharmacology), a journal based in Ireland.

More context: the Gonadorelin compound page, all human trials.